Known targets — ChEMBL curated mechanism
PDE4APDE4BPDE4CPDE4DPDE7APDE7BPDE8APDE8B
The experimentally established mechanism targets of Flavoxate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flavoxate SCHEMBL29421720 | 1.00 | LMNA (1.00) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL124540 | 0.99 | LMNA (0.98) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL29395220 | 0.99 | LMNA (0.98) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL1650335 | 0.98 | LMNA (0.96) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Flavoxate SCHEMBL7061192 | 0.95 | LMNA (0.90) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL10549683 | 0.92 | LMNA (0.85) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| SCHEMBL10707910 | 0.91 | LMNA (0.84) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL11035366 | 0.91 | LMNA (0.83) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL10709825 | 0.91 | LMNA (0.83) | LMNAHTR1AADRA1AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL10710690 | 0.89 | LMNA (0.80) | LMNAHTR1AADRA1AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6859 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638459-B2 | Method of diagnosing overactive bladder disorder | UNIVERSITY OF PORTSMOUTH HIGHER EDUCATION CORPORATION (GB) | 2026-05-26 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-3346842-B1 | STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME | NOVONESIS PLANT BIOSOLUTIONS AS (DK) | 2026-03-25 | — | — | EP | claimed |
| EP-4706766-A2 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | ADS Therapeutics LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-12496357-B2 | Compositions and methods for treating sickle cell disease | YALE UNIVERSITY (US) | 2025-12-16 | — | — | US | claimed |
| US-12485177-B2 | Topical ophthalmological compositions | ADS THERAPEUTICS LLC (US) | 2025-12-02 | — | — | US | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| US-5266347-A | Preparing in fermentation broth; drying; separating; adding to feed to prevent fungal attack during storage | DUCOA L.P. (US) | 1993-11-30 | — | — | US | claimed |
| US-5165937-A | Urinary disorders | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1992-11-24 | — | — | US | claimed |
| WO-1992015305-A1 | METHOD OF TREATMENT FOR ASTHMA, BRONCHOSPASM AND OBSTRUCTIVE LUNG DISEASE | BAKER CUMMINS PHARMACEUTICALS, INC. (US) | 1992-09-17 | — | — | WO | claimed |
| EP-0250374-B1 | THERAPEUTIC SYSTEM FOR CONTROLLED RELEASE OF DRUGS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 1991-05-02 | — | — | EP | claimed |
| EP-0393572-A2 | Controlled release tablets containing flavoxate | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1990-10-24 | — | — | EP | claimed |
| EP-0356192-A2 | Prevention & treatment of liver abscesses in animals | SMITHKLINE BEECHAM CORPORATION (US) | 1990-02-28 | — | — | EP | claimed |
| US-4769236-A | Medicaments with a high degree of solubility and method for their production | ELAN CORPORATION, PLC (IE) | 1988-09-06 | — | — | US | claimed |
| EP-0250374-A1 | Therapeutic system for controlled release of drugs | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 1987-12-23 | — | — | EP | claimed |
| EP-0063490-A1 | Lactation improvement method | ELI LILLY AND COMPANY (US) | 1982-10-27 | — | — | EP | claimed |
| US-4336250-A | VIRGINIAMYCIN OR ELFAMYCIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-06-22 | — | — | US | claimed |